Skip to main content
Top
Published in: BMC Nephrology 1/2022

Open Access 01-12-2022 | Levofloxacin | Case report

Granulomatous interstitial nephritis with CTLA-4 haploinsufficiency: a case report

Authors: Kaori Kohatsu, Tomo Suzuki, Madoka Takimoto, Katsuomi Matsui, Akinori Hashiguchi, Junki Koike, Sayuri Shirai

Published in: BMC Nephrology | Issue 1/2022

Login to get access

Abstract

Background

Cytotoxic T lymphocyte antigen-4 (CTLA-4) is an essential inhibitory regulator of immune activation. CTLA-4 haploinsufficiency is known to be associated with dysregulation of FOXP3+ regulatory T cells, hyperactivation of effector T cells, and lymphocytic infiltration of multiple organs. However, there have only been a few reports of renal involvement with CTLA-4. Herein, we present a case of acute granulomatous tubulointerstitial nephritis (TIN) in a patient with CTLA-4 haploinsufficiency.

Case presentation

A 44-year-old man presented with a 3-week history of fever and malaise, and subsequently developed acute kidney injury (AKI) a few days after treatment with levofloxacin (LVFX). A kidney biopsy and immunohistochemical staining revealed granulomatous TIN with dominantly infiltrating CD4+ T cells. General symptoms and renal impairment showed improvement after discontinuation of LVFX and initiation of oral steroids. However, they worsened following steroid tapering. Further, a colon biopsy analysis showed similar findings to the renal tissue analysis. We suspected that granulomatous TIN was possibly associated with CTLA-4 haploinsufficiency. Therefore, the patient was transferred to another hospital for further treatment of CTLA-4 haploinsufficiency using immunosuppressive agents.

Conclusions

There have been few reports regarding renal involvement of CTLA-4 haploinsufficiency. In the present case, granulomatous TIN could have arisen due to instability of immune regulatory functions, such as CTLA-4 haploinsufficiency, and treatment with LVFX could have triggered immunologic activation and severe inflammation as well as renal dysfunction.
Literature
1.
go back to reference Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T, Miyara M, Fehervari Z, et al. CTLA-4 control over FOXP3+ regulatory T cell function. Science. 2008;322:271–5.CrossRefPubMed Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T, Miyara M, Fehervari Z, et al. CTLA-4 control over FOXP3+ regulatory T cell function. Science. 2008;322:271–5.CrossRefPubMed
2.
go back to reference Friedline RH, Brown DS, Nguyen H, Kornfeld H, Lee J, Zhang Y, et al. CD4+ regulatory T cells require CTLA-4 for the maintenance of systemic tolerance. J Exp Med. 2009;206:421–34.CrossRefPubMedPubMedCentral Friedline RH, Brown DS, Nguyen H, Kornfeld H, Lee J, Zhang Y, et al. CD4+ regulatory T cells require CTLA-4 for the maintenance of systemic tolerance. J Exp Med. 2009;206:421–34.CrossRefPubMedPubMedCentral
3.
go back to reference Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity. 1995;3:541–7.CrossRefPubMed Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity. 1995;3:541–7.CrossRefPubMed
4.
go back to reference Waterhouse P, Penninger JM, Timms E, Wakeham A, Shahinian A, Lee KP, et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science. 1995;270:985–8.CrossRefPubMed Waterhouse P, Penninger JM, Timms E, Wakeham A, Shahinian A, Lee KP, et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science. 1995;270:985–8.CrossRefPubMed
5.
go back to reference Chambers CA, Sullivan TJ, Allison JP. Lymphoproliferation in CTLA-4-deficient mice is mediated by costimulation-dependent activation of CD4+ T cells. Immunity. 1997;7:885–95.CrossRefPubMed Chambers CA, Sullivan TJ, Allison JP. Lymphoproliferation in CTLA-4-deficient mice is mediated by costimulation-dependent activation of CD4+ T cells. Immunity. 1997;7:885–95.CrossRefPubMed
6.
go back to reference Kuehn HS, Ouyang W, Lo B, Deenick EK, Niemela JE, Avery DT, et al. Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4. Science. 2014;345:1623–7.CrossRefPubMedPubMedCentral Kuehn HS, Ouyang W, Lo B, Deenick EK, Niemela JE, Avery DT, et al. Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4. Science. 2014;345:1623–7.CrossRefPubMedPubMedCentral
7.
go back to reference Schubert D, Bode C, Kenefeck R, Hou TZ, Wing JB, Kennedy A, et al. Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations. Nat Med. 2014;20:1410–6.CrossRefPubMedPubMedCentral Schubert D, Bode C, Kenefeck R, Hou TZ, Wing JB, Kennedy A, et al. Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations. Nat Med. 2014;20:1410–6.CrossRefPubMedPubMedCentral
8.
go back to reference Mignon F, Méry JP, Mougenot B, Ronco P, Roland J, Morel-Maroger L. Granulomatous interstitial nephritis. Adv Nephrol Necker Hosp. 1984;13:219–45.PubMed Mignon F, Méry JP, Mougenot B, Ronco P, Roland J, Morel-Maroger L. Granulomatous interstitial nephritis. Adv Nephrol Necker Hosp. 1984;13:219–45.PubMed
10.
go back to reference Bijol V, Mendez GP, Nosé V, Rennke HG. Granulomatous interstitial nephritis: a clinicopathologic study of 46 cases from a single institution. Int J Surg Pathol. 2006;14:57–63.CrossRefPubMed Bijol V, Mendez GP, Nosé V, Rennke HG. Granulomatous interstitial nephritis: a clinicopathologic study of 46 cases from a single institution. Int J Surg Pathol. 2006;14:57–63.CrossRefPubMed
11.
go back to reference Javaud N, Belenfant X, Stirnemann J, Laederich J, Ziol M, Callard P, et al. Renal granulomatoses: a retrospective study of 40 cases and review of the literature. Medicine. 2007;86:170–80.CrossRefPubMed Javaud N, Belenfant X, Stirnemann J, Laederich J, Ziol M, Callard P, et al. Renal granulomatoses: a retrospective study of 40 cases and review of the literature. Medicine. 2007;86:170–80.CrossRefPubMed
12.
go back to reference Ramalakshmi S, Bastacky S, Johnson JP. Levofloxacin-induced granulomatous interstitial nephritis. Am J Kidney Dis. 2003;41:E7.CrossRefPubMed Ramalakshmi S, Bastacky S, Johnson JP. Levofloxacin-induced granulomatous interstitial nephritis. Am J Kidney Dis. 2003;41:E7.CrossRefPubMed
14.
go back to reference Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711–23.CrossRefPubMedPubMedCentral Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711–23.CrossRefPubMedPubMedCentral
15.
go back to reference Izzedine H, Gueutin V, Gharbi C, Mateus C, Robert C, Routier E, et al. Kidney injuries related to ipilimumab. Investig New Drugs. 2014;32:769–73.CrossRef Izzedine H, Gueutin V, Gharbi C, Mateus C, Robert C, Routier E, et al. Kidney injuries related to ipilimumab. Investig New Drugs. 2014;32:769–73.CrossRef
16.
go back to reference Voskens CJ, Goldinger SM, Loquai C, Robert C, Kaehler KC, Berking C, et al. The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. PLoS One. 2013;8:e53745.CrossRefPubMedPubMedCentral Voskens CJ, Goldinger SM, Loquai C, Robert C, Kaehler KC, Berking C, et al. The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. PLoS One. 2013;8:e53745.CrossRefPubMedPubMedCentral
17.
go back to reference Forde PM, Rock K, Wilson G, O’Byrne KJ. Ipilimumab-induced immune-related renal failure–a case report. Anticancer Res. 2012;32:4607–8.PubMed Forde PM, Rock K, Wilson G, O’Byrne KJ. Ipilimumab-induced immune-related renal failure–a case report. Anticancer Res. 2012;32:4607–8.PubMed
18.
go back to reference Thajudeen B, Madhrira M, Bracamonte E, Cranmer LD. Ipilimumab granulomatous interstitial nephritis. Am J Ther. 2015;22:e84–7.CrossRefPubMed Thajudeen B, Madhrira M, Bracamonte E, Cranmer LD. Ipilimumab granulomatous interstitial nephritis. Am J Ther. 2015;22:e84–7.CrossRefPubMed
19.
go back to reference Murakami N, Borges TJ, Yamashita M, Riella LV. Severe acute interstitial nephritis after combination immune-checkpoint inhibitor therapy for metastatic melanoma. Clin Kidney J. 2016;9:411–7.CrossRefPubMedPubMedCentral Murakami N, Borges TJ, Yamashita M, Riella LV. Severe acute interstitial nephritis after combination immune-checkpoint inhibitor therapy for metastatic melanoma. Clin Kidney J. 2016;9:411–7.CrossRefPubMedPubMedCentral
20.
go back to reference Belliere J, Meyer N, Mazieres J, Ollier S, Boulinguez S, Delas A, et al. Acute interstitial nephritis related to immune checkpoint inhibitors. Br J Cancer. 2016;115:1457–61.CrossRefPubMedPubMedCentral Belliere J, Meyer N, Mazieres J, Ollier S, Boulinguez S, Delas A, et al. Acute interstitial nephritis related to immune checkpoint inhibitors. Br J Cancer. 2016;115:1457–61.CrossRefPubMedPubMedCentral
21.
go back to reference Fadel F, El Karoui K, Knebelmann B. Anti-CTLA4 antibody- induced lupus nephritis. N Engl J Med. 2009;361:211–2.CrossRefPubMed Fadel F, El Karoui K, Knebelmann B. Anti-CTLA4 antibody- induced lupus nephritis. N Engl J Med. 2009;361:211–2.CrossRefPubMed
22.
go back to reference Ise W, Kohyama M, Nutsch KM, Lee HM, Suri A, Unanue ER, et al. CTLA-4 suppresses the pathogenicity of self antigen-specific T cells by cell-intrinsic and cell-extrinsic mechanisms. Nat Immunol. 2010;11:129–35.CrossRefPubMed Ise W, Kohyama M, Nutsch KM, Lee HM, Suri A, Unanue ER, et al. CTLA-4 suppresses the pathogenicity of self antigen-specific T cells by cell-intrinsic and cell-extrinsic mechanisms. Nat Immunol. 2010;11:129–35.CrossRefPubMed
Metadata
Title
Granulomatous interstitial nephritis with CTLA-4 haploinsufficiency: a case report
Authors
Kaori Kohatsu
Tomo Suzuki
Madoka Takimoto
Katsuomi Matsui
Akinori Hashiguchi
Junki Koike
Sayuri Shirai
Publication date
01-12-2022
Publisher
BioMed Central
Published in
BMC Nephrology / Issue 1/2022
Electronic ISSN: 1471-2369
DOI
https://doi.org/10.1186/s12882-022-02999-x

Other articles of this Issue 1/2022

BMC Nephrology 1/2022 Go to the issue